Beijing Huarui Dingxin Technology Co., Ltd

Main objectives: 1. To evaluate the safety and tolerability of HRN01 tablets after single and multiple oral administration in healthy subjects; 2. To evaluate the effect of food (high-fat and high-calorie meal) on the pharmacokinetics of HRN01 tablets. Secondary objectives: 1. To evaluate the pharmacokinetic characteristics of HRN01 tablets after single and multiple oral administration in healthy subjects; 2. To evaluate the metabolism and excretion characteristics of HRN01 tablets in healthy subjects; 3. To evaluate the effect of single administration of HRN01 tablets on the QTc interval of healthy subjects; 4. To evaluate the safety and tolerability of oral administration of HRN01 tablets in healthy subjects in the postprandial state (high-fat and high-calorie meal). Exploratory objectives: To explore the pharmacodynamic indicators of HRN01 tablets after multiple oral administration in healthy subjects.

To evaluate the efficacy and safety of dextrabeprazole sodium for injection in the treatment of acute non-variceal upper gastrointestinal bleeding

To evaluate the pharmacokinetic characteristics of different doses of dexrabeprazole sodium for injection, as well as the effects on gastric pH of healthy volunteers, and to evaluate safety. To analyze the dose-effect correlation between the pharmacokinetic and pharmacodynamic parameters of dexrabeprazole sodium for injection, and to compare the pharmacokinetic exposure of dexrabeprazole sodium for injection, to explore the appropriate dose range of dexrabeprazole sodium for injection, and to provide a theoretical basis for later clinical trials.